NHS National Pharmaceuticals - Everolimus and terminated agreement products
key details
| Value | £18,720,512 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 |
| Deadline | 26 Apr 2021 |
| Procedure | open |
| OCID | ocds-h6vhtk-02a471 |
Awards (15)
This procurement was awarded to 15 suppliers. Values shown are per-award; the notice total is £18,720,512.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Accord-UK Ltd shared | · | · | active |
| Bowmed Ibisqus Limited shared | · | · | active |
| Bristol Laboratories Limited shared | · | · | active |
| Crescent Pharma Ltd shared | · | · | active |
| Dr.Reddy's Laboratories (UK) Limited shared | · | · | active |
| Drugsrus Ltd shared | · | · | active |
| Fresenius Kabi Limited shared | · | · | active |
| Martindale Pharma shared | · | · | active |
| Medreich PLC shared | · | · | active |
| Milpharm Ltd/aurobinbdo shared | · | · | active |
| Mylan shared | · | · | active |
| Ranbaxy UK shared | · | · | active |
| Selective Supplies Ltd. shared | · | · | active |
| Teva UK Limited shared | · | · | active |
| Torrent Pharma UK Ltd shared | · | · | active |
description
Potential periods of call-offs under the framework agreement:Everolimus: All regions: to commence as soon as possible with an end date of 01/03/2022Oral Products: All regions: to commence as soon as possible with an end date of 28/02/2022Hospital Only Products: DLS, DNE, DNW, DLN and DSW regions: to commence as soon as possible with an end date 31/01/2022
notice history
2 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 9 Apr 2021 | Contract notice (F02) | Earlier regulations | 007424-2021 |
| 28 Sept 2021 | Contract award notice (F03) | Earlier regulations | 024061-2021 |
more from The NHS Commissioning Board (operating under the name of NHS England)
- Implementation of GP referral pathway to NHS CPCS · £1,700,000 · 12 May 2022
- NHS England and NHS Improvement - Independent Clinical Reviews into Deaths in Custody – South East Health & Justice, Detained Estates · 29 Apr 2022
- Provision of Benchmarking Performance Against the Learning Disability Improvement Standards for NHS Trusts · £800,000 · 18 Mar 2022
- PMO Support for the Cancer Healthcare and AI in Health and Care Programmes · £2,000,000 · 3 Mar 2022
- NHS Framework for the North of England, Branded Medicine · £863,999,552 · 1 Mar 2022
- NHS Framework for Midlands and East, Branded Medicines – Tranche A and Annual · £216,078,796 · 22 Feb 2022
- NHS National Generic Pharmaceuticals Wave 13 · £1,637,875,080 · 14 Jan 2022
- Targeted Lung Health Check Programme: External Quality Assurance of Radiologists · £800,000 · 22 Dec 2021
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.